Shares of Cadence Pharmaceuticals Inc. plunged 61.7 percent after the company reported that its intravenous acetaminophen drug, Acetavance, failed to significantly reduce acute postoperative pain over placebo in a pivotal study. (BioWorld Today)
Shares of Cadence Pharmaceuticals Inc. plunged 61.7 percent after the company reported that its intravenous acetaminophen drug, Acetavance, failed to significantly reduce acute postoperative pain over placebo in a pivotal study. (BioWorld Today)
Research and discovery tools giant Invitrogen Corp. is expanding its portfolio yet again, with an agreement to acquire privately held CellzDirect Inc. for $57 million in cash. (BioWorld Today)
Research and discovery tools giant Invitrogen Corp. is expanding its portfolio yet again, with an agreement to acquire privately held CellzDirect Inc. for $57 million in cash. (BioWorld Today)
